GlassScriptPhysician profile
Yun Bunch
NPI 1164031563
$1,427.26
in general payments reported to CMS, 2019-2025
15 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $248 · 2022: $12.19 · 2023: $491 · 2024: $380 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $531.36 | 2023-2025 | |
| Alkermes, INC. | $248.09 | 2021 | |
| Lundbeck LLC | $196.73 | 2023-2025 | Rexulti |
| Almatica Pharma LLC | $65.21 | 2024 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $60.27 | 2023 | Rexulti |
| Neurocrine Biosciences, INC. | $50.13 | 2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $48.21 | 2023 | Qelbree |
| Axsome Therapeutics, INC. | $46.78 | 2023 | Auvelity |
| Corium, LLC | $40.10 | 2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.34 | 2023 | |
| Janssen Pharmaceuticals, INC | $29.08 | 2022-2024 | Spravato |
| Bausch Health US, LLC | $21.02 | 2024 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $18.62 | 2023 | Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $18.30 | 2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $15.02 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yun Bunch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.